SCOHIA PHARMA, Inc. is pleased to announce the initiation of a Phase 1 multiple-dose clinical trial for SCO-240, an SSTR5 antagonist. This study is a randomized, single-center, double-blind, placebo-controlled trial conducted in Japan, targeting healthy adult males. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacological effects of SCO-240 following multiple-dose administration. This study is being conducted with the support of the Japan Agency for Medical Research and Development (AMED).
For more details on this clinical trial, please refer to the following:
https://jrct.niph.go.jp
（Please search for “jRCT2051240252.”）
About SCO-240, an SSTR５ antagonist
SCO-240 is an orally available, once-daily, SSTR5 antagonist under development for the treatment of growth hormone related disorders such as pediatric GH deficiency. Somatostatin is a peptide hormone secreted by the pituitary gland, pancreas, and gastrointestinal endocrine cells that regulates the secretion of endocrine hormones via five G-protein-coupled receptors (Somatostatin receptor, SSTR1–5). We primarily focused on SSTR5 and identified SCO-240, an orally available selective SSTR5 antagonist. Despite extensive research, the in vivo physiological role of SSTR5 in humans remains unknown. We conducted a Phase 1 trial in healthy individuals to evaluate the single-dose profile of SCO-240. Notably, SCO-240 stimulated a robust growth hormone (GH) secretion without affecting the secretion of other pituitary hormones. This is the first clinical report, which suggests that SSTR5 antagonist has a pivotal role in stimulating GH secretion in humans. Overall, SCO-240 is safe and well-tolerated and exhibits once-daily oral dosing potential.
SCO-240 has been selected as one of the‘FY2024 Support Programs for Orphan Drug Prior to Designation’of AMED.
For more information on SCO-240, please also visit https://www.scohia.com/eng/sys/pipeline/sco-240/
About SCOHIA PHARMA, Inc.:
SCOHIA PHARMA, Inc. is a drug discovery company focused on the discovery and development of new treatments addressing unmet medical needs with a high level of expertise in endocrine, cardiovascular, renal, and metabolic systems. For more information about SCOHIA PHARMA, Inc., please visit https://www.scohia.com/wp/eng/